A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07744126 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Telisotuzumab Adizutecan
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Fluorouracil

Sponsor

AbbVie